{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:04:00Z","timestamp":1787162640694,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:00:00Z","timestamp":1719705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Psoriatic disease, a chronic immune-mediated systemic inflammatory condition, significantly impairs patients\u2019 quality of life. The advent of highly targeted biological therapies has transformed treatment strategies, emphasizing the importance of selecting the most effective and cost-efficient option. Secukinumab, an IL-17A inhibitor, has demonstrated efficacy and safety in treating moderate-to-severe plaque psoriasis (PsO). However, long-term real-world data on its effectiveness and persistence rate are limited. Methods: This retrospective study, conducted across eight Italian dermatology centers, aimed to evaluate the 6-year persistence rate and effectiveness of secukinumab in patients with PsO. Additionally, the study investigated the onset of psoriatic arthritis during treatment. Results: Overall, 166 adult patients were analyzed. Their median age was 53.9 years. The mean BMI was 26.5. Of the 166 patients, 64 were bio-experienced while 102 were bio-na\u00efve. A progressive reduction in PsO severity measured by PASI scores over 6 years of treatment was revealed: the PASI score decreased from a baseline value of 18.1 (\u00b19.1) to 0.7 (\u00b11.6) after 6 years of follow-up. Adverse events, including mucocutaneous fungal infections and cardiovascular disturbances, were reported in 19.9% of patients. The persistence rate was 86.8% at 24 months, decreasing to 66.4% at 72 months. Psoriatic arthritis onset during treatment was observed in 15 (9.0%) of patients. Conclusions: This study highlights the sustained effectiveness and favorable safety profile of secukinumab over 6 years, providing valuable real-world evidence. Understanding the long-term persistence rate and predictors of discontinuation could help clinicians optimize treatment decisions and improve patient outcomes in PsO management. We found that the absence of scalp PsO, no involvement of the genital area and normal weight were the best factors of persistence in secukinumab treatment in the long term.<\/jats:p>","DOI":"10.3390\/jcm13133864","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:06:07Z","timestamp":1719824767000},"page":"3864","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Dermatology Unit, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-4071","authenticated-orcid":false,"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Dermatology Unit, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9232","authenticated-orcid":false,"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS, 00168 Rome, Italy"},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Di Nardo","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lazzeri","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mugheddu","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department Medical Sciences and Public Health, University of Cagliari, 09042 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-6718","authenticated-orcid":false,"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica DISSAL, Universit\u00e0 di Genova, Ospedale Policlinico San Martino\u2014IRCCS, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-054X","authenticated-orcid":false,"given":"Riccardo","family":"Balestri","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Psoriasis Outpatient Service, APSS, 38122 Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3574","authenticated-orcid":false,"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0507-0633","authenticated-orcid":false,"given":"Gabriele","family":"Biondi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vellucci","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-7720","authenticated-orcid":false,"given":"Filomena","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, IDI-IRCCS, Dermatological Research Hospital, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-0045","authenticated-orcid":false,"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS, 00168 Rome, Italy"},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8623-777X","authenticated-orcid":false,"given":"Claudia","family":"Paganini","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rech","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Psoriasis Outpatient Service, APSS, 38122 Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Claudio","family":"Cozzani","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica DISSAL, Universit\u00e0 di Genova, Ospedale Policlinico San Martino\u2014IRCCS, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-1402","authenticated-orcid":false,"given":"Laura","family":"Atzori","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department Medical Sciences and Public Health, University of Cagliari, 09042 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Montesu","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS, 00168 Rome, Italy"},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rubegni","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jdv.18329","article-title":"Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis, long-term results from an interim analysis of the SERENA study","volume":"36","author":"Augustin","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., Damiani, G., Dapavo, P., and Dini, V. (2024). Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis, a retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1341708"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/1346-8138.16926","article-title":"Real-world retention rates and effectiveness of secukinumab in psoriasis, Results from a multicenter cohort study (RAILWAY)","volume":"50","author":"Tada","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e15958","DOI":"10.1111\/dth.15958","article-title":"Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand, Characteristics, effectiveness, and safety","volume":"35","author":"Asawanonda","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ajd.13895","article-title":"Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)","volume":"63","author":"Foley","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13555-021-00675-w","article-title":"Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions, Results from the REALIA Study","volume":"12","author":"Foley","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards personalized medicine in psoriasis: Current progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2229465","DOI":"10.1080\/09546634.2023.2229465","article-title":"Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan, a retrospective database study","volume":"34","author":"Wang","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/cts.13583","article-title":"Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China, A real-world multicenter retrospective study","volume":"16","author":"Ding","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e15794","DOI":"10.1111\/dth.15794","article-title":"Should we be concerned about gastrointestinal-related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real-life study","volume":"35","author":"Diotallevi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e15929","DOI":"10.1111\/dth.15929","article-title":"Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting, Multicenter study in 384 Spanish patients","volume":"35","author":"Chicharro","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2200868","DOI":"10.1080\/09546634.2023.2200868","article-title":"Long-term efficacy and safety of secukinumab in real life, a 240 weeks multicenter study from Southern Italy","volume":"34","author":"Dastoli","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"ref_14","unstructured":"Ka\u00e7ar, N., Balc\u0131, D.D., Do\u011fan, S., T\u00fcrkmen, M., G\u00f6n\u00fclal, M., and \u00c7\u0131nar, G. (Asian. Pac. J. Allergy Immunol., 2022). Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey, a multicenter retrospective study and systematic review of the literature, Asian. Pac. J. Allergy Immunol., Epub ahead of print."},{"key":"ref_15","first-page":"e146","article-title":"High adherence to secukinumab in patients with moderate to severe psoriasis, a long-term multicenter study in a daily practice setting","volume":"62","author":"Armesto","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_16","first-page":"e15510","article-title":"Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal","volume":"35","author":"Morais","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1111\/jdv.18087","article-title":"Long-term drug survival of secukinumab in real life in the era of novel biologics, a 5-year, retrospective study, including difficult-to-treat areas","volume":"36","author":"Sotiriou","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2147\/CCID.S416149","article-title":"Long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis, 42-month results from the SUPREME 2.0 study","volume":"16","author":"Russo","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s13555-022-00867-y","article-title":"Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis, Results from a Retrospective ENHANCE Study","volume":"13","author":"Nguyen","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14890","DOI":"10.1111\/exd.14890","article-title":"Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice","volume":"33","author":"Zhou","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug Survival of Interleukin (IL) 17 and IL 23 Inhibitors for the Treatment of Psoriasis, A Retrospective Multi country, Multicentric Cohort Study","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ljad113.108","DOI":"10.1093\/bjd\/ljad113.108","article-title":"P80 Real-world evidence of the effectiveness of secukinumab in patients with psoriasis with and without scalp involvement from the British Association of Dermatologists Biologics and Immunomodulators Register","volume":"188","author":"Savage","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_23","unstructured":"(2024, May 30). Living EuroGuiDerm Guideline for the Systemic Treatment of Psoriasis Vulgaris. Available online: www.guidelines.edf.one\/guidelines."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe, efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2), a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic Burden of Psoriasis in the United States, A Systematic Review","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e15375","DOI":"10.1111\/dth.15375","article-title":"Pharmacoeconomic study of biologics for psoriasis treatment based on real-world drug survival","volume":"35","author":"Saisyo","year":"2022","journal-title":"Dermatol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3864\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:17Z","timestamp":1760108897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,30]]},"references-count":29,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13133864"],"URL":"https:\/\/doi.org\/10.3390\/jcm13133864","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,30]]}}}